Plain-English translation of NCT06794593 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a phase 2 trial testing whether camostat—a medication that may reduce kidney inflammation and damage—can help protect kidney function in people with chronic kidney disease. The researchers will compare how the medication affects patients with kidney disease against healthy volunteers to understand if it truly offers kidney protection.
Chronic kidney disease often gets worse over time, and current treatments don't work well enough for all patients. This study aims to find out whether this medication could be a new way to slow down kidney damage and help people maintain better kidney function.
You likely qualify if…
You likely don't qualify if…
You will attend screening visits where blood and urine tests will check if you qualify. If enrolled, you will take the medication for a period of time while your kidney function is monitored through regular blood and urine tests. The study also includes a healthy control group—people without kidney disease—who will participate in similar testing to help researchers compare results.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Denmark